Exhibit 99



Contact:  Rodney A. Young, CEO or Doug Nesbit, CFO (952-933-2291)

             LECTEC CORPORATION REPORTS SALE OF CONDUCTIVE BUSINESS

        PROCEEDS FROM SALE OF CONDUCTIVE BUSINESS PROVIDES CASH INFUSION



MAY 1, 2001 - - MINNETONKA, MN - LECTEC CORPORATION (NASDAQ NATIONAL MARKET:
LECT) today reported it has closed the sale of certain assets used in its
conductive products division pursuant to an Asset Purchase Agreement dated
November 17, 2000 among LecTec Corporation, The Ludlow Company LP and Sherwood
Services AG. LecTec will receive cash for this transaction in exchange for the
assets of its conductive products division as detailed in the agreement. The
proceeds from the transaction will be used to pay off the balance on the
company's line of credit with Wells Fargo Business Credit, Inc., and fund the
growth of the over-the-counter (OTC) topical drug delivery patch business.

"The proceeds from this asset sale provide us with two benefits, the infusion of
a sizeable amount of cash and the freeing up of additional space. We will
utilize the additional space for manufacturing and warehousing space, as we
execute our topical over-the-counter patch strategy with our TheraPatch and
contract manufacturing businesses." Commented Rodney A. Young, LecTec
Corporation's Chairman, CEO and President.

LecTec is a health care and consumer products company that develops,
manufactures and markets products based on its advanced skin interface
technologies. Primary products include a complete line of over-the-counter
therapeutic patches.

This press release contains forward-looking statements that may include
statements regarding intent, belief or current expectations of the company and
its management. These forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that may cause the
company's actual results to differ materially from the results discussed in
these statements. Factors that might cause such differences include, but are not
limited to, buying patterns of major customers, competitive forces including new
products or pricing pressures, costs associated with and acceptance of the
company's TheraPatch brand strategy, impact of interruptions to production,
dependence on key personnel, need for regulatory approvals, the ability to
satisfy funding requirements for operating needs, expansion or capital
expenditures and other risks and uncertainties detailed from time to time in the
company's filings with the Securities and Exchange Commission.
                                      # # #